Management of Febrile Neutropenia

Warning Signs and Initial Assessment

• The American Society of Clinical Oncology recommends immediate assessment of circulatory and respiratory function, with vigorous resuscitation if necessary, in patients with febrile neutropenia 2, 3
• Signs and symptoms of infection may be minimal in neutropenic patients, especially those on corticosteroids, requiring vigilance for any patient at risk who presents unwell, hypotensive, with low-grade fever or even afebrile 3, 4
• Hypotension (systolic BP <90 mmHg) is a high-risk warning sign in febrile neutropenia, requiring prompt attention 4
• Respiratory distress or hypoxemia are high-risk warning signs in febrile neutropenia, necessitating immediate intervention 2, 3

Management and Antibiotic Selection

• The European Society for Medical Oncology recommends monotherapy with anti-pseudomonal cephalosporin (e.g., cefepime 2g IV every 8 hours) or carbapenem as appropriate for most patients with febrile neutropenia 2
• Combination therapy with β-lactam plus aminoglycoside may be preferred for high-risk patients (prolonged neutropenia, bacteremia) 2, 3
• Obtain blood cultures from peripheral vein and all indwelling catheters before starting antibiotics, and collect other relevant cultures (urine, sputum, skin swabs) as clinically indicated 3, 4

Site-Specific Management

• Central line infections require addition of vancomycin if line infection is suspected, and administration through the line when possible 7, 8
• Cellulitis necessitates addition of vancomycin to broaden coverage against skin pathogens 7, 8
• Candidosis requires initiation of fluconazole, with early switch to alternative antifungal if inadequate response 7, 8

Assessment of Response and Follow-up

• Frequent clinical assessment (every 2-4 hours in severe cases) is crucial in managing febrile neutropenia, with daily evaluation of fever trends, bone marrow and renal function 1, 5
• If afebrile and ANC ≥0.5×10^9/L at 48 hours, consider changing to oral antibiotics for low-risk patients, and discontinuing aminoglycoside for high-risk patients on dual therapy 1
• If still febrile at 48 hours, continue initial antibacterial therapy for clinically stable patients, and broaden antibiotic coverage and seek infectious disease consultation for clinically unstable patients 1, 6

Duration of Therapy

• Discontinue antibiotics if neutrophil count ≥0.5×10^9/L, patient is asymptomatic, afebrile for 48 hours, and blood cultures negative 1
• Exception: High-risk cases with acute leukemia or post-high-dose chemotherapy may continue antibiotics for up to 10 days or until neutrophil recovery 1